An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exicure to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company, announced its participation in key investor conferences for September 2021. The events include Citi’s 16th Annual Biopharma Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference with a presentation on September 13 at 7:00 AM ET, and the Baird Global Healthcare Conference on September 14 at 9:40 AM ET. The company is focused on developing therapeutics using its Spherical Nucleic Acid technology, with candidates targeting Friedreich’s ataxia and advanced solid tumors.
Positive
None.
Negative
None.
CHICAGO, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following investor conferences during the month of September:
H.C. Wainwright 23rd Annual Global Investment Conference Presentation Time: 7:00 AM ET Virtual webcast here
Monday, September 13, 2021
Baird Global Healthcare Conference Presentation Time: 9:40 AM ET Tuesday, September 14, 2021
Replays of the H.C. Wainwright webcast will be available on Exicure’s website for 30 days following the event.
About Exicure, Inc. Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.
What investor conferences is Exicure (XCUR) participating in September 2021?
Exicure is participating in Citi’s 16th Annual Biopharma Conference, H.C. Wainwright 23rd Annual Global Investment Conference, and Baird Global Healthcare Conference.
When is the H.C. Wainwright conference presentation by Exicure (XCUR)?
Exicure's presentation at the H.C. Wainwright conference is on September 13, 2021, at 7:00 AM ET.
What is Exicure (XCUR) focusing on with its drug development?
Exicure is developing therapeutics targeting neurology, immuno-oncology, and inflammatory diseases using its Spherical Nucleic Acid technology.
Is Exicure (XCUR) involved in any clinical trials?
Yes, Exicure's cavrotolimod is in a Phase 1b/2 clinical trial for patients with advanced solid tumors.
What is the significance of Spherical Nucleic Acid technology for Exicure (XCUR)?
Spherical Nucleic Acid technology provides unique chemical and biological advantages for targeting diseases not typically addressed by other therapeutics.
